# Zim Laboratories Ltd (ZIMLAB)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹100.11
Day Change: +1%
52W High: ₹126.95
52W Low: ₹59.72
Market Cap: ₹530 Cr

## Valuation
P/E: 68.68
P/B: 1.86
EPS: ₹1.44
Book Value: ₹53.27
Dividend Yield: 0%

## Returns
1Y Return: 26.82%

## Profitability
ROE: 0%
ROCE: 8.01%
Debt/Equity: 0.49
Revenue Growth: 12.8%
Profit Growth: 9.8%
EBITDA Margin: 9.1%
Operating Margin: 7.16%

## About
Zim Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Zim Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Quarterly Report: Board Meeting Intimation for Consideration And Approval Of The Audited Standalone And Consolidated Financial Results For The Year Eneded 31St March, 2026.
- BSE Filing: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

## Access
Current tier: anonymous
More history: Register free to see 12 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:06.460Z
Price History Updated: 2026-05-18T22:59:20.235Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:59:20.235Z
Quant Updated: 2026-05-18T22:59:20.235Z
Sentiment Updated: 2026-05-18T22:59:20.235Z
Financials Status: current
Financials Updated: 2026-05-18T21:31:30.725Z
Financials Last Attempt: 2026-05-18T21:31:30.725Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹362.89 Cr
Operating Profit: ₹26.7 Cr (OPM 7.36%)
Net Profit: ₹12.17 Cr
Tax: ₹5.84 Cr

## Annual P&L History
FY25: Rev ₹362.89Cr | PAT ₹12.17Cr | OPM 7.36%
FY24: Rev ₹355.51Cr | PAT ₹17.25Cr | OPM 7.53%
FY23: Rev ₹388.73Cr | PAT ₹24.43Cr | OPM 9.07%

## Balance Sheet (FY25)
Total Assets: ₹472.02 Cr
Total Liabilities: ₹219.79 Cr
Borrowings: ₹117.68 Cr
Cash: ₹1.95 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Anwar Siraj Daud M.Pharm, Executive Chairman & MD
- Shyam Mohan Patro, Chief Financial Officer
- Piyush Siddheshwar Nikhade C.S., Company Secretary & Compliance Officer
- Niraj Pukhraj Dhadiwal, Director of Business Development & Executive Director
- Zulfiquar Murtaza Kamal, Director of Finance & Executive Director

---
Source: rupiya.io/stocks/zimlab
Disclaimer: For research and education only. Not investment advice.